Health Care·Biotechnology·$185.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.98 | N/A | +3.7% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $3.98 | N/A | +3.7% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed a cautious optimism about future growth driven by their pipeline. They emphasized the significance of innovation in their strategy.
Management highlighted ongoing investments in R&D as a key focus.
They noted the importance of maintaining strong market positions despite competitive pressures.
Amgen's earnings report shows a positive surprise in EPS, which contributed to a slight increase in stock price. The lack of revenue data and guidance may leave investors cautious, but management's focus on R&D suggests a commitment to future growth. The stock's modest rise reflects a generally favorable reception to the earnings beat.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AMERIPRISE FINL INC
Apr 24, 2023